SCHEMBL3308762

SCHEMBL3308762

c1ccc(-c2nccc3nc(Nc4ccc(N5CCOCC5)cc4)nn23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.62
PLK4 O00444 4/20 0.57
INSR P06213 1/20 0.57
JAK3 P52333 3/20 0.54
PTK2 Q05397 3/20 0.54
ABL1 P00519 1/20 0.53
NTRK1 P04629 1/20 0.53
YES1 P07947 1/20 0.53
KDR P35968 1/20 0.53
KIT P10721 1/20 0.52
FLT3 P36888 1/20 0.52
AXL P30530 1/20 0.51
MAPK8 P45983 2/20 0.51
MAPK10 P53779 1/20 0.51
IGF1R P08069 2/20 0.50
AURKA O14965 2/20 0.49
AURKB Q96GD4 1/20 0.49
SLC2A1 P11166 1/20 0.49
TP53 P04637 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14354061 0.88 DGAT1 (0.48) JAK2PLK4INSRJAK3PTK2
SCHEMBL3301223 0.83 KDR (0.52) JAK2JAK3PTK2ABL1KDR
SCHEMBL2144948 0.82 JAK2 (0.74) JAK2PLK4INSRJAK3PTK2
SCHEMBL28254694 0.77 JAK2 (1.00) JAK2PLK4JAK3PTK2KDR
SCHEMBL3195106 0.77 JAK2 (0.67) JAK2INSRJAK3PTK2MAPK8
SCHEMBL15273104 0.76 TTK (0.52) JAK2PLK4INSRJAK3PTK2
SCHEMBL3305445 0.75 JAK2 (0.44) JAK2JAK3PTK2KDR
SCHEMBL15268777 0.75 JAK2 (0.57) JAK2PLK4INSRJAK3PTK2
SCHEMBL2145013 0.74 JAK2 (0.73) JAK2INSRJAK3PTK2TP53
SCHEMBL3204359 0.74 JAK2 (0.72) JAK2PLK4INSRJAK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 JAK2 26/4885PLK4 324/4885INSR 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.